Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the appointment of BBI Solutions as manufacturing partner for the COVID-19 test. Alastair talk us through the details, how the prototype is working and the next steps in bringing it to market. Also discussed is the existing agreement with Daewoong Pharmaceutical which has been expanded to include the SARS-CoV-2 neutralising Affimer reagents and the development of the high throughput COVID-19 test with Adeptrix.

Avacta Group also announced that it has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The source of

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow to $15

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a safe and